{"id":"gatifloxacin-ophthalmic-solution-0-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival irritation"},{"rate":null,"effect":"Eye discomfort"},{"rate":null,"effect":"Taste perversion"},{"rate":null,"effect":"Photophobia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a fourth-generation fluoroquinolone, gatifloxacin works by binding to and inhibiting DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for bacterial DNA replication and repair. This dual mechanism results in rapid bactericidal activity against a broad spectrum of gram-positive and gram-negative ocular pathogens. When formulated as an ophthalmic solution, it achieves high local concentrations in ocular tissues to treat bacterial infections of the eye.","oneSentence":"Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:03.749Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Bacterial corneal ulcers"},{"name":"Other bacterial ocular infections"}]},"trialDetails":[{"nctId":"NCT03696342","phase":"PHASE3","title":"Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2018-10-01","conditions":"Conjunctivitis, Bacterial","enrollment":46},{"nctId":"NCT02980523","phase":"PHASE2","title":"Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2015-03","conditions":"Bacterial Conjunctivitis","enrollment":150},{"nctId":"NCT01218737","phase":"PHASE3","title":"Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2009-01","conditions":"Ocular Infection and Inflammation","enrollment":101},{"nctId":"NCT01330355","phase":"PHASE3","title":"Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis","status":"TERMINATED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-05","conditions":"Bacterial Conjunctivitis","enrollment":33},{"nctId":"NCT00874887","phase":"PHASE4","title":"A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-03","conditions":"Anti-biotic Resistance","enrollment":66},{"nctId":"NCT00824070","phase":"PHASE1","title":"Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Cataract Extraction","enrollment":105},{"nctId":"NCT00892918","phase":"NA","title":"Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2009-06","conditions":"Primary Pterygium","enrollment":40},{"nctId":"NCT00703313","phase":"PHASE4","title":"Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT00651586","phase":"PHASE2","title":"Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-10","conditions":"Acute Bacterial Corneal Ulcers, Bacterial Keratitis","enrollment":129},{"nctId":"NCT00347828","phase":"PHASE4","title":"Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2006-06","conditions":"Eye Infection, Infection","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ZYMAR®"],"phase":"marketed","status":"active","brandName":"gatifloxacin ophthalmic solution 0.3%","genericName":"gatifloxacin ophthalmic solution 0.3%","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription. Used for Bacterial conjunctivitis, Bacterial corneal ulcers, Other bacterial ocular infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}